High-dose chemotherapy with AHPCS for the treatment of breast cancer. The University of Colorado results.
In summary, the administration of effective high-dose chemotherapy regimens at a time of minimal tumor burden should eradicate disease in selected breast cancer patients who otherwise have little chance of prolonged disease-free survival following standard-dose treatments. The results are particularly promising for breast cancer patients with high-risk stage II/III, and NED or responsive stage IV disease. Many studies to confirm these hypotheses are in progress. New high-dose chemotherapy regimens, together with methods to reduce tumor contamination of the graft and new treatment modalities should improve the current results in patients with breast cancer.
University of Colorado Bone Marrow Transplant Program, Denver, USA.
P J
PJ
Cagnoni
E J
EJ
Shpall
S I
SI
Bearman
M
M
Ross
R B
RB
Jones
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001781:Blood Component Removal / Q000379:methods; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000628:therapy*; D002986:Clinical Trials as Topic; D003120:Colorado; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009360:Neoplastic Cells, Circulating; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous